Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 19;8(2):e10408. doi: 10.1002/btm2.10408

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors. Bioengineering & Translational Medicine published by Wiley Periodicals LLC on behalf of American Institute of Chemical Engineers.

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

FUS‐enhanced R15 delivery inhibited tumor growth and improved survival. (a) Experimental protocol of the survival study. Treatment = nanoconjugates (R2 or R15) with or without FUS, BLI, bioluminescence imaging; MRI, magnetic resonance imaging. (b) T1‐weighted contrast MRI confirmed the BBB opening. The increased accumulation of MR contrast indicated the enhanced drug delivery after FUS treatment. (c) Bioluminescence imaging results showed that R15 + FUS combination therapy achieved significant tumor suppression 5 days after the FUS treatment (Day 19). (d) Survival curves of five experimental groups. Only R15 + FUS combination therapy significantly improved survival benefits compared to the control group. Data correspond to mean ± SEM. *p < 0.05